Search bioRxiv⌕ Search

Biology subjects

Saei, H.

Publications and source records attributed to Saei, H..

2 recordsLinked to original sources

MucOneUp: A Simulation Framework for MUC1-VNTR Variant Benchmarking

SummaryVariable number tandem repeats (VNTRs) in the MUC1 gene cause autosomal dominant tubulointerstitial kidney disease when disrupted by frameshift variants, but the GC-rich 60-bp repeat structure (20-125 copies) challenges variant detection. While tools like VNtyper enable MUC1 variant calling, no gold-standard benchmarking datasets exist for systematic performance evaluation. We present MucOneUp, a specialized simulation framework for generating MUC1-VNTR reference sequences with targeted variants and platform-specific sequencing reads (Illumina, Oxford Nanopore, PacBio). MucOneUp employs Markov chain-based repeat generation, supports diploid simulation with customizable variant placement, and includes additional analysis modules for SNaPshot assay simulation and exploratory frameshift analysis. We validate MucOneUp through a multi-variant, cross-platform benchmark of six tool-platform combinations using 13 distinct frameshift variants and investigate VNTR length effects on detection. Availability and implementationMucOneUp is accessible at no cost under the MIT License at https://github.com/berntpopp/MucOneUp and archived on Zenodo (DOI: 10.5281/zenodo.19740406). Contactbernt.popp@charite.de Supplementary informationSupplementary data are provided with this manuscript.

bioinformatics↗

Therapeutic splice modulation of COL4A5 reinstates collagen IV assembly in an organoid model of X-linked Alport syndrome

Kidney organoids are an emerging tool for disease modeling, especially genetic diseases. Among them, X-linked Alport syndrome (XLAS) is a hematuric nephropathy affecting the glomerular basement membrane (GBM) secondary to pathogenic variations in the COL4A5 gene encoding the 5 subunit of type IV collagen [5(IV)]. In patients carrying pathogenic variations affecting splicing, the use of antisense oligonucleotides (ASOs) offers immense therapeutic hope. In this study, we develop a framework combining the use of patient-derived cells and kidney organoids to provide evidence of the therapeutic efficacy of ASOs in XLAS patients. Using multiomics analysis, we describe the development of GBM in wild-type and mutated human kidney organoids. We show that GBM maturation is a dynamic process, which requires long organoid culture. Then, using semi-automated quantification of 5(IV) at basement membranes in organoids carrying the splicing variants identified in patients, we demonstrate the efficacy of ASO treatment for 5(IV) restoration. These data contribute to our understanding of the development of GBM and pave the way for a therapeutic screening platform for patients.

genetics↗